



Universiteit
Leiden
The Netherlands

Inclusion body myositis : a nationwide study

Badrising, U.A.

Citation

Badrising, U. A. (2006, September 20). *Inclusion body myositis : a nationwide study*. Retrieved from <https://hdl.handle.net/1887/4567>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4567>

Note: To cite this publication please use the final published version (if applicable).

Reference list

APPENDIX B

REFERENCE LIST

1. Chou SM. Myxovirus-like structures in a case of human chronic polymyositis. *Science* 1967; 158(807):1453-1455.
2. Carpenter S, Karpatis G, Wolfe L. Virus-like filaments and phospholipid accumulation in skeletal muscle. Study of a histochemically distinct chronic myopathy. *Neurology* 1970; 20(9):889-903.
3. Yunis EJ, Samaha FJ. Inclusion body myositis. *Lab Invest* 1971; 25(3):240-248.
4. Carpenter S, Karpatis G, Heller I, Eisen A. Inclusion body myositis: a distinct variety of idiopathic inflammatory myopathy. *Neurology* 1978; 28(1):8-17.
5. Mikol J, Felten-Papaiconomou A, Ferchal F, Perol Y, Gautier B, Haguenu M et al. Inclusion-body myositis: clinicopathological studies and isolation of an adenovirus type 2 from muscle biopsy specimen. *Ann Neurol* 1982; 11(6):576-581.
6. Chad D, Good P, Adelman L, Bradley WG, Mills J. Inclusion body myositis associated with Sjogren's syndrome. *Arch Neurol* 1982; 39(3):186-188.
7. Riggs JE, Schochet SS, Jr., Gutmann L, McComas CF, Rogers JS. Inclusion body myositis and chronic immune thrombocytopenia. *Arch Neurol* 1984; 41(1):93-95.
8. Yood RA, Smith TW. Inclusion body myositis and systemic lupus erythematosus. *J Rheumatol* 1985; 12(3):568-570.
9. Danon MJ, Perurena OH, Ronan S, Manaligod JR. Inclusion body myositis associated with systemic sarcoidosis. *Can J Neurol Sci* 1986; 13(4):334-336.
10. Khraishi MM, Jay V, Keystone EC. Inclusion body myositis in association with vitamin B12 deficiency and Sjogren's syndrome. *J Rheumatol* 1992; 19(2):306-309.
11. Ytterberg SR, Roelofs RI, Mahowald ML. Inclusion body myositis and renal cell carcinoma. Report of two cases and review of the literature. *Arthritis Rheum* 1993; 36(3):416-421.
12. Soden M, Boundy K, Burrow D, Blumbergs P, Ahern M. Inclusion body myositis in association with rheumatoid arthritis. *J Rheumatol* 1994; 21(2):344-346.
13. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. *Ann Neurol* 1984; 16(2):193-208.

APPENDIX B

14. Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. *Ann Neurol* 1984; 16(2):209-215.
15. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. III: Immunoelectron microscopy aspects of cell-mediated muscle fiber injury. *Ann Neurol* 1986; 19(2):112-125.
16. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. IV: Cell-mediated cytotoxicity and muscle fiber necrosis. *Ann Neurol* 1988; 23(2):168-173.
17. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. V: Identification and quantitation of T8+ cytotoxic and T8+ suppressor cells. *Ann Neurol* 1988; 23(5):493-499.
18. Lotz BP, Engel AG, Nishino H, Stevens JC, Litchy WJ. Inclusion body myositis. Observations in 40 patients. *Brain* 1989; 112 (Pt 3):727-747.
19. Kelly JJ, Jr., Madoc-Jones H, Adelman LS, Andres PL, Munsat TL. Total body irradiation not effective in inclusion body myositis. *Neurology* 1986; 36(9):1264-1266.
20. Dau PC. Leukocytapheresis in inclusion body myositis. *J Clin Apheresis* 1987; 3(3):167-170.
21. Wintzen AR, Bots GT, de Bakker HM, Hulshof JH, Padberg GW. Dysphagia in inclusion body myositis. *J Neurol Neurosurg Psychiatry* 1988; 51(12):1542-1545.
22. Verma A, Bradley WG, Adesina AM, Sofferman R, Pendlebury WW. Inclusion body myositis with cricopharyngeus muscle involvement and severe dysphagia. *Muscle Nerve* 1991; 14(5):470-473.
23. Danon MJ, Friedman M. Inclusion body myositis associated with progressive dysphagia: treatment with cricopharyngeal myotomy. *Can J Neurol Sci* 1989; 16(4):436-438.
24. Darrow DH, Hoffman HT, Barnes GJ, Wiley CA. Management of dysphagia in inclusion body myositis. *Arch Otolaryngol Head Neck Surg* 1992; 118(3):313-317.
25. Danon MJ, Friedman M. Inclusion body myositis with cricopharyngeus muscle involvement and severe dysphagia. *Muscle Nerve* 1992; 15(1):115.
26. Litchy WJ, Engel AG. Inclusion body myositis with cricopharyngeus muscle involvement and severe dysphagia. *Muscle Nerve* 1992; 15(1):115.

REFERENCE LIST

27. Mendell JR, Sahenk Z, Gales T, Paul L. Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments. *Arch Neurol* 1991; 48(12):1229-1234.
28. Askanas V, Serdaroglu P, Engel WK, Alvarez RB. Immunolocalization of ubiquitin in muscle biopsies of patients with inclusion body myositis and oculopharyngeal muscular dystrophy. *Neurosci Lett* 1991; 130(1):73-76.
29. Askanas V, Engel WK, Alvarez RB. Light and electron microscopic localization of beta-amyloid protein in muscle biopsies of patients with inclusion-body myositis. *Am J Pathol* 1992; 141(1):31-36.
30. Bilak M, Askanas V, Engel WK. Strong immunoreactivity of alpha 1-antichymotrypsin co-localizes with beta-amyloid protein and ubiquitin in vacuolated muscle fibers of inclusion-body myositis. *Acta Neuropathol (Berl)* 1993; 85(4):378-382.
31. Sarkozi E, Askanas V, Johnson SA, Engel WK, Alvarez RB. beta-Amyloid precursor protein mRNA is increased in inclusion-body myositis muscle. *Neuroreport* 1993; 4(6):815-818.
32. Askanas V, Alvarez RB, Engel WK. beta-Amyloid precursor epitopes in muscle fibers of inclusion body myositis. *Ann Neurol* 1993; 34(4):551-560.
33. Askanas V, Bilak M, Engel WK, Alvarez RB, Tome F, Leclerc A. Prion protein is abnormally accumulated in inclusion-body myositis. *Neuroreport* 1993; 5(1):25-28.
34. Askanas V, Engel WK, Bilak M, Alvarez RB, Selkoe DJ. Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau. *Am J Pathol* 1994; 144(1):177-187.
35. Sarkozi E, Askanas V, Engel WK. Abnormal accumulation of prion protein mRNA in muscle fibers of patients with sporadic inclusion-body myositis and hereditary inclusion- body myopathy. *Am J Pathol* 1994; 145(6):1280-1284.
36. Mirabella M, Alvarez RB, Engel WK, Weisgraber KH, Askanas V. Apolipoprotein E and apolipoprotein E messenger RNA in muscle of inclusion body myositis and myopathies. *Ann Neurol* 1996; 40(6):864-872.
37. Nalbantoglu J, Karpati G, Carpenter S. Conspicuous accumulation of a single-stranded DNA binding protein in skeletal muscle fibers in inclusion body myositis. *Am J Pathol* 1994; 144(5):874-882.
38. Soueidan SA, Dalakas MC. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. *Neurology* 1993; 43(5):876-879.

39. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. *N Engl J Med* 1993; 329(27):1993-2000.
40. Amato AA, Barohn RJ, Jackson CE, Pappert EJ, Sahenk Z, Kissel JT. Inclusion body myositis: treatment with intravenous immunoglobulin. *Neurology* 1994; 44(8):1516-1518.
41. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo- controlled study. *Neurology* 1997; 48(3):712-716.
42. Hopkinson ND, Hunt C, Powell RJ, Lowe J. Inclusion body myositis: an underdiagnosed condition? *Ann Rheum Dis* 1993; 52(2):147-151.
43. Mhiri C, Gherardi R. Inclusion body myositis in French patients. A clinicopathological evaluation. *Neuropathol Appl Neurobiol* 1990; 16(4):333-344.
44. Lindberg C, Persson LI, Bjorkander J, Oldfors A. Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases. *Acta Neurol Scand* 1994; 89(2):123-131.
45. Lindberg C, Oldfors A, Tarkowski A. Restricted use of T cell receptor V genes in endomysial infiltrates of patients with inflammatory myopathies. *Eur J Immunol* 1994; 24(11):2659-2663.
46. Fyhr IM, Moslemi AR, Tarkowski A, Lindberg C, Oldfors A. Limited T-cell receptor V gene usage in inclusion body myositis. *Scand J Immunol* 1996; 43(1):109-114.
47. Askanas V, Engel WK, Alvarez RB. Fourteen newly recognized proteins at the human neuromuscular junctions- and their nonjunctional accumulation in inclusion-body myositis. *Ann N Y Acad Sci* 1998; 841:28-56.
48. Eisen A, Berry K, Gibson G. Inclusion body myositis (IBM): myopathy or neuropathy? *Neurology* 1983; 33(9):1109-1114.
49. Joy JL, Oh SJ, Baysal AI. Electrophysiological spectrum of inclusion body myositis. *Muscle Nerve* 1990; 13(10):949-951.
50. Beyenburg S, Zierz S, Jerusalem F. Inclusion body myositis: clinical and histopathological features of 36 patients. *Clin Invest* 1993; 71(5):351-361.
51. Sayers ME, Chou SM, Calabrese LH. Inclusion body myositis: analysis of 32 cases. *J Rheumatol* 1992; 19(9):1385-1389.

REFERENCE LIST

52. Askanas V, McFerrin J, Alvarez RB, Baque S, Engel WK. Beta APP gene transfer into cultured human muscle induces inclusion- body myositis aspects. *Neuroreport* 1997; 8(9-10):2155-2158.
53. Verschuuren JJ, Badrising UA, Wintzen AR, van Engelen BG, van der Hoeven H, Hoogendijk JE. Inclusion Body Myositis. In: Emery AEH, editor. *Diagnostic Criteria for Neuromuscular Disorders*. London: Royal Society of Medicine Press, European Neuromuscular Centre, 1997: 81-84.
54. Statistics Netherlands. *Statistical yearbook of the Netherlands*. 1999 ed. The Hague: Thieme-O.G., 1999.
55. Griggs RC, Askanas V, DiMauro S, Engel A, Karpatai G, Mendell JR et al. Inclusion body myositis and myopathies. *Ann Neurol* 1995; 38(5):705-713.
56. Amato AA, Barohn RJ. Idiopathic inflammatory myopathies. *Neurol Clin* 1997; 15(3):615-648.
57. Felice KJ, Relva GM, Conway SR. Further observations on forearm flexor weakness in inclusion body myositis. *Muscle Nerve* 1998; 21(5):659-661.
58. Ringel SP, Kenny CE, Neville HE, Giorno R, Carry MR. Spectrum of inclusion body myositis. *Arch Neurol* 1987; 44(11):1154-1157.
59. Phillips BA, Cala LA, Thickbroom GW, Melsom A, Zilko PJ, Mastaglia FL. Patterns of muscle involvement in inclusion body myositis: clinical and magnetic resonance imaging study. *Muscle Nerve* 2001; 24(11):1526-1534.
60. Felice KJ, North WA. Inclusion body myositis in Connecticut: observations in 35 patients during an 8-year period. *Medicine (Baltimore)* 2001; 80(5):320-327.
61. Amato AA, Gronseth GS, Jackson CE, Wolfe GI, Katz JS, Bryan WW et al. Inclusion body myositis: clinical and pathological boundaries. *Ann Neurol* 1996; 40(4):581-586.
62. Rose MR, McDermott MP, Thornton CA, Palenski C, Martens WB, Griggs RC. A prospective natural history study of inclusion body myositis: implications for clinical trials. *Neurology* 2001; 57(3):548-550.
63. Badrising UA, Maat-Schieman M, van Duinen SG, Breedveld E, van Doorn P, van Engelen B et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. *Neurology* 2000; 55(9):1385-1387.

64. Wintzen AR, Badrising UA, Roos RA, Vielvoye J, Liauw L, Pauwels EK. Dysphagia in ambulant patients with Parkinson's disease: common, not dangerous. *Can J Neurol Sci* 1994; 21(1):53-56.
65. Barthel DW, Mahoney FI. Functional evaluation; the Barthel index. *Maryland State Med J* 1965; 14:61-65.
66. Collen FM, Wade DT, Robb GF, Bradshaw CM. The Rivermead Mobility Index: a further development of the Rivermead Motor Assessment. *Int Disabil Stud* 1991; 13(2):50-54.
67. Brooke MH. A clinician's view of neuromuscular disorders. 2nd ed. Baltimore: Williams and Wilkins, 1986.
68. Aids to the examination of the peripheral nervous system. 1st ed. London: Bailliere Tindall, 1990.
69. van der Ploeg RJO. Hand-held dynamometry. Rijksuniversiteit Groningen, 1992.
70. Peng A, Koffman BM, Malley JD, Dalakas MC. Disease progression in sporadic inclusion body myositis: observations in 78 patients. *Neurology* 2000; 55(2):296-298.
71. Badrising UA, Maat-Schieman MLC, van Houwelingen JC, van Doorn PA, van Duijn SG, van Engelen BGM et al. Inclusion body myositis-Clinical features and clinical course of the disease in 64 patients. *J Neurol* 2005; 252(12):1448-1454.
72. Barkhaus PE, Periquet MI, Nandedkar SD. Quantitative electrophysiologic studies in sporadic inclusion body myositis. *Muscle Nerve* 1999; 22(4):480-487.
73. Pestronk A, Drachman DB. Polymyositis: reduction of acetylcholine receptors in skeletal muscle. *Muscle Nerve* 1985; 8(3):233-239.
74. Niks EH, Badrising UA, Verschuuren JJ, van Dijk JG. Decremental response of the nasalis and hypothenar muscles in myasthenia gravis. *Muscle Nerve* 2003; 28(2):236-238.
75. Wang FC, De P, V, Gerard P, Delwaide PJ. Prognostic value of decremental responses to repetitive nerve stimulation in ALS patients. *Neurology* 2001; 57(5):897-899.
76. Bernstein LP, Antel JP. Motor neuron disease: decremental responses to repetitive nerve stimulation. *Neurology* 1981; 31(2):204-207.
77. Killian JM, Wilfong AA, Burnett L, Appel SH, Boland D. Decremental motor responses to repetitive nerve stimulation in ALS. *Muscle & Nerve* 1994; 17(7):747-754.

REFERENCE LIST

78. Badrising UA, Maat-Schieman ML, Ferrari MD, Zwinderman AH, Wessels JA, Breedveld FC et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. *Ann Neurol* 2002; 51(3):369-372.
79. Schipper RE, Schreuder GM, D'Amaro J, Oudshoorn M. HLA gene and haplotype frequencies in Dutch blood donors. *Tissue Antigens* 1996; 48(5):562-574.
80. Garlepp MJ, Laing B, Zilko PJ, Ollier W, Mastaglia FL. HLA associations with inclusion body myositis. *Clin Exp Immunol* 1994; 98(1):40-45.
81. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. *Medicine (Baltimore)* 1991; 70(6):360-374.
82. Koffman BM, Sivakumar K, Simonis T, Stroncek D, Dalakas MC. HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies. *J Neuroimmunol* 1998; 84(2):139-142.
83. Wirtz PW, Roep BO, Schreuder GM, van Doorn PA, van Engelen BG, Kuks JB et al. HLA class I and II in Lambert-Eaton myasthenic syndrome without associated tumor. *Hum Immunol* 2001; 62(8):809-813.
84. Koffman BM, Rugiero M, Dalakas MC. Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. *Muscle Nerve* 1998; 21(1):115-117.
85. Askanas V, Engel WK. Sporadic inclusion-body myositis and its similarities to Alzheimer disease brain. Recent approaches to diagnosis and pathogenesis, and relation to aging. *Scand J Rheumatol* 1998; 27(6):389-405.
86. Villanova M, Kawai M, Lubke U, Oh SJ, Perry G, Six J et al. Rimmed vacuoles of inclusion body myositis and oculopharyngeal muscular dystrophy contain amyloid precursor protein and lysosomal markers. *Brain Res* 1993; 603(2):343-347.
87. Pruitt JN, Showalter CJ, Engel AG. Sporadic inclusion body myositis: counts of different types of abnormal fibers. *Ann Neurol* 1996; 39(1):139-143.
88. Leff RL, Miller FW, Hicks J, Fraser DD, Plotz PH. The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy. *Medicine (Baltimore)* 1993; 72(4):225-235.
89. Rau R, Schleusser B, Herborn G, Karger T. Long-term treatment of destructive rheumatoid arthritis with methotrexate. *J Rheumatol* 1997; 24(10):1881-1889.

90. Weinblatt ME, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC et al. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. *Arthritis Rheum* 1994; 37(10):1492-1498.
91. Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. *Neurology* 2001; 56(3):323-327.
92. Walter MC, Lochmuller H, Toepfer M, Schlotter B, Reilich P, Schroder M et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. *J Neurol* 2000; 247(1):22-28.
93. Black P. Why is the prevalence of allergy and autoimmunity increasing? *Trends Immunol* 2001; 22(7):354-355.
94. Phillips BA, Zilko PJ, Mastaglia FL. Prevalence of sporadic inclusion body myositis in Western Australia. *Muscle Nerve* 2000; 23(6):970-972.
95. Kapur N, Hunt I, Lunt M, McBeth J, Creed F, Macfarlane G. Primary care consultation predictors in men and women: a cohort study. *British Journal of General Practice* 2005; 55(511):108-113.
96. Nicholson GA, McLeod JG, Morgan G, Meerkin M, Cowan J, Bretag A et al. Variable distributions of serum creatine kinase reference values. Relationship to exercise activity. *J Neurol Sci* 1985; 71:233-245.
97. Lindberg C, Trysberg E, Tarkowski A, Oldfors A. Anti-T-lymphocyte globulin treatment in inclusion body myositis: A randomized pilot study. *Neurology* 2003; 61(2):260-262.
98. Tawil R, Griggs R, Thornton C, Kissel J, Mendell J, Genge A et al. Randomized pilot trial of high-dose beta INF-1a in patients with inclusion body myositis. *Neurology* 2004; 63(4):718-720.
99. Banwell BL, Engel AG. AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis. *Neurology* 2000; 54(5):1033-1041.
100. Nakano S, Shinde A, Ito H, Ito H, Kusaka H. Messenger RNA degradation may be inhibited in sporadic inclusion body myositis. *Neurology* 2005; 65(3):420-425.

List of abbreviations

APPENDIX C

LIST OF ABBREVIATIONS

A β	amyloid β
AIDs	autoimmune disorders
CI	confidence interval
CK	creatine kinase
CMAPs	compound muscle action potentials
EM	electron microscopy
ENMC	European Neuromuscular Center
HLA	human leucocyte antigen
IBM	inclusion body myositis
LEMS	Lambert-Eaton myasthenic syndrome
LM	light microscopy
MHC	major histocompatibility complex
MMT	manual muscle testing
MND	motor neuron disease
MRC	British Medical Research Council
MTX	methotrexate
MUAP	motor unit action potential
NMJ	neuromuscular junction
RNS	repetitive nerve stimulation
sCK	serum creatine kinase
SFEMG	single fiber electromyography
QMT	quantitative muscle testing

APPENDIX C

Curriculum Vitae

APPENDIX D

CURRICULUM VITAE

Umesh Arvind Badrising was born on July 10, 1969 in Paramaribo, Suriname. He finished his secondary school at the Rembrandt Scholen Gemeenschap in Leiden in 1987. He then started his medical study at the Leiden University. During his study he tutored courses in anatomy and participated in research towards the relationship between class-specific rheuma factors and age at the Department of Rheumatology and research concerning swallowing dysfunction in Parkinson's disease at the Department of Neurology. He passed his "doctoraal examen" (M.Sc.) in 1992 and obtained his medical degree (M.D.) in 1994. He then started as a resident and from 1995 as a research fellow at the Department of Neurology of the Leiden University Medical Center (Prof. Dr. R.A.C. Roos, Prof. Dr. A.R. Wintzen). Since 2004 he works as a neurologist at the van Weel Bethesda hospital in Dirksland, South Holland.

Umesh Arvind Badrising werd geboren op 10 juli 1969 te Paramaribo, Suriname. In 1987 behaalde hij zijn VWO diploma aan de Rembrandt Scholen Gemeenschap in Leiden. Aansluitend begon hij zijn studie geneeskunde aan de Universiteit Leiden. Gedurende de studie begeleidde hij als student-assistent practica anatomie en werkte hij mee aan onderzoek naar de relatie tussen klasse-specifieke reumafactoren en leeftijd op de afdeling reumatologie en naar slikstoornissen bij de ziekte van Parkinson op de afdeling neurologie. Het doctoraal examen behaalde hij in 1992 en het artsexamen in 1994. Hierna was hij als assistent geneeskundige niet in opleiding (1994) en vanaf 1995 als assistent geneeskundige in opleiding tot klinisch onderzoeker (AGIKO) werkzaam op de afdeling neurologie van het Leids Universitair Medisch Centrum (opleiders Prof. Dr. R.A.C. Roos, Prof. Dr. A.R. Wintzen). Sinds 2004 is hij werkzaam als neuroloog in het van Weel Bethesda ziekenhuis in Dirksland (Z.H.).

APPENDIX D

List of publications

APPENDIX E

LIST OF PUBLICATIONS

U.A. Badrising, M.L.C. Maat-Schieman, J.C. van Houwelingen, P.A. van Doorn, S.G. van Duinen, B.G.M. van Engelen, C.G. Faber, J.E. Hoogendijk, A.E. de Jager, P.J. Koehler, M. de Visser, J.J.G.M. Verschuuren, and A.R. Wintzen. Inclusion body myositis-Clinical features and clinical course of the disease in 64 patients. *J Neurol* 2005; 252:1448-1454.

U.A. Badrising, G.M.Th. Schreuder, M.J. Giphart, K. Geleijns, J.J.G.M. Verschuuren, A.R. Wintzen and the Dutch IBM Study Group. Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis. *Neurology* 2004; 63:2396-2398.

E.H. Niks, U.A. Badrising, J.J.G.M. Verschuuren, and J.G. van Dijk. Decremental response of the nasalis and hypothenar muscles in myasthenia gravis. *Muscle Nerve* 2003; 28(2):236-238.

U.A. Badrising, M.L.C. Maat-Schieman, M.D. Ferrari, A.H. Zwinderman, F.C. Breedveld, P. van Doorn, B. van Engelen, J.E. Hoogendijk, C.J. Höweler, A.E. de Jager, F.G.I. Jennekens, P.J. Koehler, M. de Visser, A. Viddeleer, J.J.G.M. Verschuuren, and A.R. Wintzen. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. *Ann Neurol* 2002; 51:369-372.

M.F.G. van der Meulen, J.E. Hoogendijk, K.G.M. Moons, H. Veldman, U.A. Badrising, J.H.J. Wokke. Rimmed vacuoles and the added value of SMI-31 staining in diagnosing sporadic inclusion body myositis. *Neuromusc Dis* 2001; 11(5):447-451.

U.A. Badrising, M.L.C. Maat-Schieman, S.G. van Duinen, F. Breedveld, P.A. van Doorn, B.G.M. van Engelen, F. van den Hoogen, J.E. Hoogendijk, C.J. Höweler, A.E. de Jager, F.G.I. Jennekens, P.J. Koehler, H. van der Leeuw, M. de Visser, J.J.G.M. Verschuuren, and A.R. Wintzen. Epidemiology of inclusion body myositis in the Netherlands: A nationwide study. *Neurology* 2000; 55:1385-1387.

U.A. Badrising, M.L.C. Maat-Schieman, S.G. van Duinen, J.G. van Dijk, J.J.G.M. Verschuuren and A.R. Wintzen. 'Inclusion body'-myositis. *Ned Tijdschr Geneesk* 1998; 142(11):553-557.

G.J.D. Hengstman, B.G.M. van Engelen, U.A. Badrising, F.H.J. van den Hoogen, W.J. van Venrooij. Presence of the anti-Jo-1 autoantibody excludes inclusion body myositis. *Ann Neurol* 1998; 44(3):423-423.

J.J.G.M. Verschuuren, U.A. Badrising, A.R. Wintzen, B.G.M. van Engelen, H. van der Hoeven, and J. Hoogendijk. Inclusion body myositis. In Emery AEH, editor. Diagnostic Criteria for Neuromuscular Disorders, chapter 17. London: Royal Society of Medicine Press, European Neuromuscular Centre, 1997; 81-84.

A.R. Wintzen, U.A. Badrising, R.A.C. Roos, J. Vielvoye, L. Liauw, and E.K.J. Pauwels. Dysphagia in ambulant patients with Parkinson's disease: common, not dangerous. *Can J Neurol Sci* 1994; 21(1):53-56.

APPENDIX E

A.R. Wintzen, U.A. Badrising, R.A.C. Roos, J. Vielvoye, L. Liauw, and E.K.J. Pauwels. Influence of bolus volume on hyoid movements in normal individuals with Parkinson's disease. *Can J Neurol Sci* 1994;21(1):57-59.

Acknowledgement / Nawoord

APPENDIX F

ACKNOWLEDGEMENT / NAWOORD

The result of this thesis could only be achieved thanks to the cooperation of many persons. I wish to express my extraordinary appreciation and thanks to all patients who have actively contributed to the study and to their supporting partners. And of course I wish to thank the referring neurologists for their indispensable cooperation.

Dit proefschrift kon alleen tot stand komen dankzij de medewerking van velen. Mijn bijzondere waardering en dank gaat uit naar alle patiënten die op inspannende wijze hebben meegewerkt aan het onderzoek en evenzeer naar de ondersteuning die hierbij door hun partners gegeven werd. Uiteraard was de welwillende medewerking van de verwijzend neurologen onmisbaar.

